Summary

This document provides an overview of drugs used in mood disorders. It covers topics such as neurotransmitters involved in depression, drugs indicated for bipolar disorder, and the typical time for antidepressants to show improvement in patients. Further subsections detail standardized diagnostic criteria and pathophysiological mechanisms of depression.

Full Transcript

Drugs Used in Mood Disorders \#\#\# \*\*Slide 1: Overview of Drugs Used in Mood Disorders\*\* 1\. \*\*Which neurotransmitters are primarily involved in the pathophysiology of depression?\*\* \- A. Serotonin, norepinephrine, dopamine \- B. GABA, acetylcholine, histamine \- C. Cortisol, estrogen,...

Drugs Used in Mood Disorders \#\#\# \*\*Slide 1: Overview of Drugs Used in Mood Disorders\*\* 1\. \*\*Which neurotransmitters are primarily involved in the pathophysiology of depression?\*\* \- A. Serotonin, norepinephrine, dopamine \- B. GABA, acetylcholine, histamine \- C. Cortisol, estrogen, dopamine \- D. Epinephrine, cortisol, serotonin \*\*Answer:\*\* A. Serotonin, norepinephrine, dopamine 2\. \*\*Which of the following drugs is indicated for bipolar disorder?\*\* \- A. Paroxetine \- B. Sertraline \- C. Lithium \- D. Fluoxetine \*\*Answer:\*\* C. Lithium 3\. \*\*How long does it typically take for antidepressants to show clinical improvement in patients?\*\* \- A. 1 week \- B. 2-4 weeks \- C. 5 days \- D. 3 months \*\*Answer:\*\* B. 2-4 weeks【33†source】 \-\-- \#\#\# \*\*Slide 2: Depression - DSM-5 Criteria\*\* 1\. \*\*According to DSM-5, how many symptoms must be present for a diagnosis of depression?\*\* \- A. At least 3 \- B. 5 or more \- C. 6-10 \- D. At least 2 \*\*Answer:\*\* B. 5 or more 2\. \*\*Which of the following is one of the two mandatory symptoms for a depression diagnosis according to DSM-5?\*\* \- A. Weight gain \- B. Insomnia \- C. Depressed mood \- D. Fatigue \*\*Answer:\*\* C. Depressed mood 3\. \*\*Which of the following symptoms should NOT be included when diagnosing depression according to DSM-5?\*\* \- A. Loss of interest \- B. Depressed mood \- C. Weight gain due to medical condition \- D. Psychomotor retardation \*\*Answer:\*\* C. Weight gain due to medical condition【33†source】 \-\-- \#\#\# \*\*Slide 3: Pathophysiology of Depression\*\* 1\. \*\*Which hypothesis suggests that depression is related to a deficiency in serotonin, norepinephrine, and dopamine?\*\* \- A. Neuroendocrine hypothesis \- B. Monoamine hypothesis \- C. Neurotrophic hypothesis \- D. Glutamate hypothesis \*\*Answer:\*\* B. Monoamine hypothesis 2\. \*\*Which factor is associated with a decrease in brain-derived neurotrophic factor (BDNF) in patients with depression?\*\* \- A. Glucocorticoid receptor binding \- B. Elevated norepinephrine levels \- C. Elevated serotonin levels \- D. Decreased cortisol levels \*\*Answer:\*\* A. Glucocorticoid receptor binding 3\. \*\*Which hormone dysregulation is often found in patients with depression, according to the neuroendocrine hypothesis?\*\* \- A. Prolactin \- B. Cortisol \- C. Insulin \- D. Testosterone \*\*Answer:\*\* B. Cortisol【33†source】 \-\-- \#\#\# \*\*Slide 4: Depression Symptom Mnemonic\*\* 1\. \*\*Which symptom is represented by the \"I\" in the mnemonic for depression symptoms?\*\* \- A. Irritability \- B. Insomnia \- C. Interest loss \- D. Impulsivity \*\*Answer:\*\* C. Interest loss 2\. \*\*What does the \"S\" in the depression mnemonic represent?\*\* \- A. Sleep disturbance \- B. Suicidal ideation \- C. Sadness \- D. Self-esteem issues \*\*Answer:\*\* A. Sleep disturbance 3\. \*\*Which symptom in the mnemonic indicates potential weight fluctuations?\*\* \- A. Sleep disturbance \- B. Psychomotor changes \- C. Appetite changes \- D. Energy loss \*\*Answer:\*\* C. Appetite changes【33†source】 \-\-- \#\#\# \*\*Slide 5: Normal Brain Physiology\*\* 1\. \*\*Which neurotransmitter is involved in regulating mood, appetite, and sleep?\*\* \- A. Dopamine \- B. Norepinephrine \- C. Serotonin \- D. GABA \*\*Answer:\*\* C. Serotonin 2\. \*\*What enzyme degrades serotonin and norepinephrine in the synaptic cleft?\*\* \- A. Monoamine oxidase (MAO) \- B. Acetylcholinesterase \- C. Glutaminase \- D. Catechol-O-methyltransferase (COMT) \*\*Answer:\*\* A. Monoamine oxidase (MAO) 3\. \*\*Which neurotransmitter is responsible for mood regulation and cognitive functions like memory and learning?\*\* \- A. GABA \- B. Serotonin \- C. Dopamine \- D. Norepinephrine \*\*Answer:\*\* D. Norepinephrine【33†source】 \-\-- \#\#\# \*\*Slide 6: Neurotrophic Hypothesis\*\* 1\. \*\*The neurotrophic hypothesis of depression focuses on which protein related to neural plasticity and resilience?\*\* \- A. Serotonin \- B. Brain-derived neurotrophic factor (BDNF) \- C. Cortisol \- D. Dopamine \*\*Answer:\*\* B. Brain-derived neurotrophic factor (BDNF) 2\. \*\*What effect do antidepressants have on brain-derived neurotrophic factor (BDNF) levels?\*\* \- A. Decrease BDNF levels \- B. Stabilize BDNF levels \- C. Increase BDNF levels \- D. No effect on BDNF levels \*\*Answer:\*\* C. Increase BDNF levels 3\. \*\*Which of the following factors is NOT typically associated with a reduction in BDNF levels in depression?\*\* \- A. Glucocorticoid receptor activation \- B. Chronic stress \- C. Increased norepinephrine \- D. Elevated cortisol levels \*\*Answer:\*\* C. Increased norepinephrine【33†source】 \-\-- \#\#\# \*\*Slide 7: Neuroendocrine Hypothesis\*\* 1\. \*\*Which hormone is commonly elevated in patients with depression according to the neuroendocrine hypothesis?\*\* \- A. Estrogen \- B. Insulin \- C. Cortisol \- D. Melatonin \*\*Answer:\*\* C. Cortisol 2\. \*\*Thyroid dysregulation is present in approximately what percentage of patients with depression?\*\* \- A. 5% \- B. 10% \- C. 25% \- D. 50% \*\*Answer:\*\* C. 25% 3\. \*\*What neuroendocrine factor may contribute to mood symptoms in postpartum depression?\*\* \- A. Low cortisol levels \- B. Estrogen deficiency \- C. Low prolactin levels \- D. Testosterone deficiency \*\*Answer:\*\* B. Estrogen deficiency【33†source】 \-\-- \#\#\# \*\*Slide 8: Monoamine Hypothesis\*\* 1\. \*\*Which class of drugs supports the monoamine hypothesis by increasing serotonin and norepinephrine levels?\*\* \- A. Antipsychotics \- B. SSRIs and SNRIs \- C. Benzodiazepines \- D. Anticonvulsants \*\*Answer:\*\* B. SSRIs and SNRIs 2\. \*\*Which neurotransmitter, according to the monoamine hypothesis, is NOT typically implicated in depression?\*\* \- A. Dopamine \- B. Serotonin \- C. Acetylcholine \- D. Norepinephrine \*\*Answer:\*\* C. Acetylcholine 3\. \*\*Which drug mentioned in the evidence for the monoamine hypothesis blocks central monoamine activity and can cause depression in some patients?\*\* \- A. Propranolol \- B. Fluoxetine \- C. Venlafaxine \- D. Lithium \*\*Answer:\*\* A. Propranolol【33†source】 \-\-- \#\#\# \*\*Slide 9: Neurotrophic Hypothesis\*\* 1\. \*\*What is a critical function of brain-derived neurotrophic factor (BDNF) in the brain?\*\* \- A. Regulating appetite \- B. Promoting neural plasticity and neurogenesis \- C. Increasing serotonin breakdown \- D. Inhibiting cortisol release \*\*Answer:\*\* B. Promoting neural plasticity and neurogenesis 2\. \*\*Which of the following supports the neurotrophic hypothesis in the treatment of depression?\*\* \- A. Increased BDNF levels with antidepressant therapy \- B. Increased cortisol levels in patients on antidepressants \- C. Lower dopamine levels in response to therapy \- D. Increased norepinephrine with treatment \*\*Answer:\*\* A. Increased BDNF levels with antidepressant therapy 3\. \*\*Which of the following is associated with a reduction in BDNF synthesis in the brain?\*\* \- A. Glucocorticoid receptor binding \- B. Elevated testosterone levels \- C. Low serotonin levels \- D. Increased norepinephrine activity \*\*Answer:\*\* A. Glucocorticoid receptor binding【33†source】 \-\-- \#\#\# \*\*Slide 10: Mechan ism of Antidepressants\*\* 1\. \*\*How do most antidepressants work to alleviate depression symptoms?\*\* \- A. By blocking serotonin and norepinephrine reuptake \- B. By blocking dopamine breakdown \- C. By stimulating cortisol release \- D. By increasing acetylcholine levels \*\*Answer:\*\* A. By blocking serotonin and norepinephrine reuptake 2\. \*\*Which neurotransmitter is most affected by selective serotonin reuptake inhibitors (SSRIs)?\*\* \- A. Norepinephrine \- B. Dopamine \- C. Serotonin \- D. GABA \*\*Answer:\*\* C. Serotonin 3\. \*\*Why do antidepressants typically take several weeks to show efficacy?\*\* \- A. They need time to decrease serotonin levels \- B. They require time to increase BDNF synthesis \- C. They work immediately but require close monitoring \- D. They must first decrease norepinephrine activity \*\*Answer:\*\* B. They require time to increase BDNF synthesis【33†source】 \#\#\# \*\*Slide 11: Monoamine Hypothesis\*\* 1\. \*\*The monoamine hypothesis of depression suggests that depression is related to a deficiency of which neurotransmitters?\*\* \- A. Serotonin, norepinephrine, and dopamine \- B. Glutamate, GABA, and acetylcholine \- C. Epinephrine, cortisol, and serotonin \- D. Dopamine, acetylcholine, and GABA \*\*Answer:\*\* A. Serotonin, norepinephrine, and dopamine 2\. \*\*What is one piece of evidence supporting the monoamine hypothesis?\*\* \- A. Depression has been linked to excessive serotonin levels in the brain \- B. Reserpine, which depletes monoamines, has been shown to cause depression in some patients \- C. Elevated dopamine levels are consistently found in patients with depression \- D. The monoamine hypothesis has been disproven by clinical trials \*\*Answer:\*\* B. Reserpine, which depletes monoamines, has been shown to cause depression in some patients 3\. \*\*According to the monoamine hypothesis, what role does glutamate play in depression?\*\* \- A. It is decreased in depressed patients \- B. It is unrelated to depression \- C. It is elevated in the cerebrospinal fluid of depressed patients \- D. It acts as a secondary messenger in serotonin production \*\*Answer:\*\* C. It is elevated in the cerebrospinal fluid of depressed patients \-\-- \#\#\# \*\*Slide 12: Neurotrophic Hypothesis\*\* 1\. \*\*According to the neurotrophic hypothesis, depression is associated with reduced levels of which growth factor?\*\* \- A. Nerve growth factor \- B. Brain-derived neurotrophic factor (BDNF) \- C. Epidermal growth factor \- D. Fibroblast growth factor \*\*Answer:\*\* B. Brain-derived neurotrophic factor (BDNF) 2\. \*\*What is one clinical effect of antidepressants related to the neurotrophic hypothesis?\*\* \- A. They decrease serotonin release \- B. They reduce the levels of BDNF in the brain \- C. They increase BDNF levels in the brain, promoting neurogenesis \- D. They decrease dopamine production in the limbic system \*\*Answer:\*\* C. They increase BDNF levels in the brain, promoting neurogenesis 3\. \*\*What hormonal dysregulation is frequently seen in patients with depression according to the neuroendocrine hypothesis?\*\* \- A. Low cortisol levels \- B. Elevated cortisol levels \- C. Increased estrogen levels \- D. Reduced thyroid hormone secretion \*\*Answer:\*\* B. Elevated cortisol levels \-\-- \#\#\# \*\*Slide 13: Antidepressant Mechanisms\*\* 1\. \*\*Most antidepressants work by increasing the concentration of which neurotransmitter(s) in the synaptic cleft?\*\* \- A. Serotonin and dopamine \- B. Serotonin and norepinephrine \- C. Dopamine and acetylcholine \- D. GABA and glutamate \*\*Answer:\*\* B. Serotonin and norepinephrine 2\. \*\*How do selective serotonin reuptake inhibitors (SSRIs) alleviate symptoms of depression?\*\* \- A. By blocking the reuptake of dopamine \- B. By inhibiting the enzyme that breaks down norepinephrine \- C. By blocking the reuptake of serotonin into the presynaptic neuron \- D. By increasing serotonin degradation \*\*Answer:\*\* C. By blocking the reuptake of serotonin into the presynaptic neuron 3\. \*\*Why do antidepressants typically take several weeks to show clinical efficacy?\*\* \- A. It takes time to increase serotonin and norepinephrine levels \- B. BDNF synthesis requires more than two weeks \- C. Patients must reach steady-state concentrations of the drug \- D. Dopamine levels take time to normalize \*\*Answer:\*\* B. BDNF synthesis requires more than two weeks \-\-- \#\#\# \*\*Slide 14: FDA Warning on Antidepressants\*\* 1\. \*\*What risk is associated with antidepressant use in patients younger than 25 according to the FDA warning?\*\* \- A. Increased risk of weight gain \- B. Increased risk of suicidality (suicidal ideation and behavior) \- C. Reduced efficacy in treating depression \- D. Risk of serotonin syndrome \*\*Answer:\*\* B. Increased risk of suicidality (suicidal ideation and behavior) 2\. \*\*For which trimester of pregnancy is there an association between antidepressant use and low birth weight and premature delivery?\*\* \- A. First trimester \- B. Second trimester \- C. Third trimester \- D. Throughout the entire pregnancy \*\*Answer:\*\* C. Third trimester 3\. \*\*In lactating mothers taking antidepressants, what is the recommended course of action?\*\* \- A. Discontinue breastfeeding \- B. Weigh the risks and benefits before continuing the medication \- C. Switch to a tricyclic antidepressant (TCA) \- D. Take antidepressants only during the second half of the day \*\*Answer:\*\* B. Weigh the risks and benefits before continuing the medication \-\-- \#\#\# \*\*Slide 15: Selective Serotonin Reuptake Inhibitors (SSRIs)\*\* 1\. \*\*Which receptor do SSRIs primarily target?\*\* \- A. Norepinephrine transporter (NET) \- B. Serotonin transporter (SERT) \- C. Dopamine transporter (DAT) \- D. GABA receptor \*\*Answer:\*\* B. Serotonin transporter (SERT) 2\. \*\*What is the primary indication for prescribing SSRIs?\*\* \- A. Major depressive disorder (MDD) \- B. Schizophrenia \- C. Bipolar disorder \- D. Parkinson\'s disease \*\*Answer:\*\* A. Major depressive disorder (MDD) 3\. \*\*Which SSRI is known for having a long half-life and the potential to be \"activating\"?\*\* \- A. Sertraline \- B. Paroxetine \- C. Fluoxetine \- D. Citalopram \*\*Answer:\*\* C. Fluoxetine \-\-- \#\#\# \*\*Slide 16: SSRI Pharmacokinetics\*\* 1\. \*\*Which of the following SSRIs has the longest half-life, allowing once-daily dosing?\*\* \- A. Fluoxetine \- B. Sertraline \- C. Paroxetine \- D. Escitalopram \*\*Answer:\*\* A. Fluoxetine 2\. \*\*SSRIs are primarily metabolized by which enzyme system?\*\* \- A. P-glycoprotein \- B. Cytochrome P450 (CYP) enzymes \- C. Aldehyde dehydrogenase \- D. Monoamine oxidase (MAO) \*\*Answer:\*\* B. Cytochrome P450 (CYP) enzymes 3\. \*\*Why are SSRIs generally dosed once daily?\*\* \- A. They have short half-lives \- B. They have long half-lives that allow for once-daily dosing \- C. They are metabolized quickly by the liver \- D. Patients prefer less frequent dosing \*\*Answer:\*\* B. They have long half-lives that allow for once-daily dosing \-\-- \#\#\# \*\*Slide 17: SSRI Side Effects\*\* 1\. \*\*What is the most common side effect of SSRIs related to increased serotonergic activity?\*\* \- A. Weight loss \- B. Sexual dysfunction \- C. Dry mouth \- D. Diarrhea \*\*Answer:\*\* B. Sexual dysfunction 2\. \*\*Which SSRI is associated with the highest risk of weight gain?\*\* \- A. Citalopram \- B. Paroxetine \- C. Sertraline \- D. Fluoxetine \*\*Answer:\*\* B. Paroxetine 3\. \*\*What is a notable side effect of abruptly discontinuing SSRIs?\*\* \- A. Serotonin syndrome \- B. Discontinuation syndrome with dizziness and paresthesias \- C. Hypoglycemia \- D. Hyperthermia \*\*Answer:\*\* B. Discontinuation syndrome with dizziness and paresthesias \-\-- \#\#\# \*\*Slide 18: Serotonin Syndrome\*\* 1\. \*\*What is a common sign of serotonin syndrome?\*\* \- A. Hypothermia \- B. Autonomic instability (hyperthermia, hypertension) \- C. Bradycardia \- D. Hypotension \*\*Answer:\*\* B. Autonomic instability (hyperthermia, hypertension) 2\. \*\*What drug is used to treat serotonin syndrome by blocking serotonin receptors?\*\* \- A. Lorazepam \- B. Cyproheptadine \- C. Diazepam \- D. Fluoxetine \*\*Answer:\*\* B. Cyproheptadine 3\. \*\*Which of the following is NOT a typical cause of serotonin syndrome?\*\* \- A. SSRIs \- B. S NRIs \- C. MAO inhibitors \- D. Anticholinergics \*\*Answer:\*\* D. Anticholinergics \-\-- \#\#\# \*\*Slide 19: SNRI Mechanism and Indications\*\* 1\. \*\*SNRIs block the reuptake of which neurotransmitters?\*\* \- A. Serotonin and dopamine \- B. Serotonin and norepinephrine \- C. Norepinephrine and dopamine \- D. GABA and serotonin \*\*Answer:\*\* B. Serotonin and norepinephrine 2\. \*\*Which condition, in addition to depression, is commonly treated with SNRIs?\*\* \- A. Obsessive-compulsive disorder (OCD) \- B. Neuropathic pain \- C. Bipolar disorder \- D. Schizophrenia \*\*Answer:\*\* B. Neuropathic pain 3\. \*\*Which SNRI is used for treating generalized anxiety disorder (GAD) and chronic pain conditions such as fibromyalgia?\*\* \- A. Venlafaxine \- B. Duloxetine \- C. Desvenlafaxine \- D. Sertraline \*\*Answer:\*\* B. Duloxetine \-\-- \#\#\# \*\*Slide 20: SNRI Side Effects\*\* 1\. \*\*Which side effect is most commonly associated with SNRIs, particularly at high doses?\*\* \- A. Bradycardia \- B. Hypertension \- C. Hypoglycemia \- D. Hyperthyroidism \*\*Answer:\*\* B. Hypertension 2\. \*\*What is a common gastrointestinal side effect of SNRIs?\*\* \- A. Diarrhea \- B. Nausea and vomiting \- C. Constipation \- D. Gastritis \*\*Answer:\*\* B. Nausea and vomiting 3\. \*\*SNRIs should not be combined with which of the following due to the risk of serotonin syndrome?\*\* \- A. Tricyclic antidepressants (TCAs) \- B. Monoamine oxidase inhibitors (MAOIs) \- C. Antipsychotics \- D. Beta-blockers \*\*Answer:\*\* B. Monoamine oxidase inhibitors (MAOIs) \#\#\# \*\*Slide 21: Bupropion (Wellbutrin)\*\* 1\. \*\*What is the primary mechanism of action of bupropion (Wellbutrin)?\*\* \- A. Selective serotonin reuptake inhibitor \- B. Norepinephrine and dopamine reuptake inhibitor \- C. Monoamine oxidase inhibitor \- D. Glutamate antagonist \*\*Answer:\*\* B. Norepinephrine and dopamine reuptake inhibitor 2\. \*\*Bupropion is contraindicated in patients with which of the following conditions?\*\* \- A. Anxiety disorders \- B. Seizure disorders \- C. Chronic kidney disease \- D. Hypertension \*\*Answer:\*\* B. Seizure disorders 3\. \*\*Which of the following is a benefit of bupropion compared to SSRIs?\*\* \- A. Lower risk of sexual side effects \- B. More sedating effect \- C. Increased serotonin reuptake \- D. Reduced risk of weight loss \*\*Answer:\*\* A. Lower risk of sexual side effects【48:6†source】 \-\-- \#\#\# \*\*Slide 22: New Medication - Dextromethorphan/Bupropion ER (Auvelity)\*\* 1\. \*\*What is the mechanism of action of dextromethorphan in Auvelity?\*\* \- A. NMDA receptor antagonist \- B. Serotonin reuptake inhibitor \- C. Dopamine receptor agonist \- D. GABA agonist \*\*Answer:\*\* A. NMDA receptor antagonist 2\. \*\*Which medication is combined with dextromethorphan in Auvelity to enhance its antidepressant effects?\*\* \- A. Sertraline \- B. Bupropion \- C. Fluoxetine \- D. Mirtazapine \*\*Answer:\*\* B. Bupropion 3\. \*\*What is a significant risk when combining dextromethorphan with serotonergic medications?\*\* \- A. Hypertensive crisis \- B. Hypoglycemia \- C. Serotonin syndrome \- D. Bradycardia \*\*Answer:\*\* C. Serotonin syndrome【48:13†source】 \-\-- \#\#\# \*\*Slide 23: Trazodone (Desyrel)\*\* 1\. \*\*What is the primary mechanism of action of trazodone at low doses?\*\* \- A. NMDA receptor antagonist \- B. Histamine receptor antagonist \- C. Alpha-1 receptor antagonist and 5-HT2A receptor antagonist \- D. Dopamine receptor agonist \*\*Answer:\*\* C. Alpha-1 receptor antagonist and 5-HT2A receptor antagonist 2\. \*\*Trazodone is commonly used at low doses to treat which of the following conditions?\*\* \- A. Anxiety disorders \- B. Hypertension \- C. Insomnia \- D. Bipolar disorder \*\*Answer:\*\* C. Insomnia 3\. \*\*What is a rare but serious side effect of trazodone that requires immediate medical attention?\*\* \- A. Priapism \- B. Serotonin syndrome \- C. Agranulocytosis \- D. Stevens-Johnson syndrome \*\*Answer:\*\* A. Priapism【48:13†source】 \-\-- \#\#\# \*\*Slide 24: Mirtazapine (Remeron)\*\* 1\. \*\*Which receptor is antagonized by mirtazapine to increase norepinephrine and serotonin levels?\*\* \- A. Alpha-2 adrenergic receptor \- B. Beta-adrenergic receptor \- C. Dopamine D2 receptor \- D. NMDA receptor \*\*Answer:\*\* A. Alpha-2 adrenergic receptor 2\. \*\*What is a common side effect of mirtazapine, especially at lower doses?\*\* \- A. Insomnia \- B. Weight gain \- C. Nausea \- D. Hypertension \*\*Answer:\*\* B. Weight gain 3\. \*\*Mirtazapine is less likely to cause which of the following side effects compared to SSRIs?\*\* \- A. Sexual dysfunction \- B. Weight gain \- C. Drowsiness \- D. Dry mouth \*\*Answer:\*\* A. Sexual dysfunction【48:1†source】 \-\-- \#\#\# \*\*Slide 25: NMDA Receptor Antagonists\*\* 1\. \*\*Which of the following NMDA receptor antagonists is approved for treatment-resistant depression?\*\* \- A. Ketamine \- B. Fluoxetine \- C. Lithium \- D. Sertraline \*\*Answer:\*\* A. Ketamine 2\. \*\*What is a common side effect of esketamine (Spravato), an NMDA receptor antagonist?\*\* \- A. Euphoria \- B. Dissociation \- C. Bradycardia \- D. Hypoglycemia \*\*Answer:\*\* B. Dissociation 3\. \*\*NMDA receptor antagonists are thought to work in depression by modulating which neurotransmitter system?\*\* \- A. Serotonin \- B. Glutamate \- C. Dopamine \- D. GABA \*\*Answer:\*\* B. Glutamate【48:13†source】 \-\-- \#\#\# \*\*Slide 26: Monoamine Oxidase Inhibitors (MAOIs)\*\* 1\. \*\*What is the primary mechanism of action of monoamine oxidase inhibitors (MAOIs)?\*\* \- A. Inhibition of serotonin reuptake \- B. Inhibition of the enzyme that breaks down norepinephrine, dopamine, and serotonin \- C. Activation of GABA receptors \- D. Antagonism of NMDA receptors \*\*Answer:\*\* B. Inhibition of the enzyme that breaks down norepinephrine, dopamine, and serotonin 2\. \*\*Which of the following foods should be avoided by patients taking MAOIs?\*\* \- A. Bananas \- B. Cheese \- C. Chicken \- D. Oranges \*\*Answer:\*\* B. Cheese 3\. \*\*Combining MAOIs with SSRIs can result in which life-threatening condition?\*\* \- A. Hypothyroidism \- B. Serotonin syndrome \- C. Renal failure \- D. Hyperkalemia \*\*Answer:\*\* B. Serotonin syndrome【48:5†source】 \-\-- \#\#\# \*\*Slide 27: MAOI Side Effects and Interactions\*\* 1\. \*\*Which of the following is a common side effect of MAOIs?\*\* \- A. Weight loss \- B. Orthostatic hypotension \- C. Hypertension \- D. Hyperglycemia \*\*Answer:\*\* B. Orthostatic hypotension 2\. \*\*MAOIs should not be combined with which of the following medications due to the risk of hypertensive crisis?\*\* \- A. Beta-blockers \- B. SSRIs \- C. Antipsychotics \- D. Antihistamines \*\*Answer:\*\* B. SSRIs 3\. \*\*Which of the following is a serious interaction that can occur when MAOIs are combined with sympathomimetics?\*\* \- A. Bradycardia \- B. Hypothermia \- C. Hypertensive crisis \- D. Hyperthermia \*\*Answer:\*\* C. Hypertensive crisis【48:6†source】 \-\-- \#\#\# \*\*Slide 28: Tricyclic Antidepressants (TCAs)\*\* 1\. \*\*Tricyclic antidepressants (TCAs) block the reuptake of which neurotransmitters?\*\* \- A. Serotonin and dopamine \- B. Serotonin and norepinephrine \- C. Norepinephrine and acetylcholine \- D. GABA and dopamine \*\*Answer:\*\* B. Serotonin and norepinephrine 2\. \*\*Which of the following is a serious side effect of TCA overdose?\*\* \- A. QT prolongation and cardiac arrhythmias \- B. Hyperglycemia \- C. Bradycardia \- D. Hyponatremia \*\*Answer:\*\* A. QT prolongation and cardiac arrhythmias 3\. \*\*Which TCA is most commonly prescribed for obsessive-compulsive disorder (OCD)?\*\* \- A. Amitriptyline \- B. Desipramine \- C. Clomipramine \- D. Imipramine \*\*Answer:\*\* C. Clomipramine【48:9†source】 \-\-- \#\#\# \*\*Slide 29: TCA Side Effects\*\* 1\. \*\*Which of the following side effects is associated with the anticholinergic properties of TCAs?\*\* \- A. Diarrhea \- B. Urinary retention \- C. Bradycardia \- D. Weight loss \*\*Answer:\*\* B. Urinary retention 2\. \*\*What is a common central nervous system (CNS) side effect of TCAs?\*\* \- A. Insomnia \- B. Sedation \- C. Anxiety \- D. Hallucinations \*\*Answer:\*\* B. Sedation 3\. \*\*Which receptor blockade contributes to the fall risk associated with TCAs? \*\* \- A. Alpha-1 adrenergic receptor blockade \- B. Beta-2 adrenergic receptor blockade \- C. NMDA receptor blockade \- D. GABA receptor blockade \*\*Answer:\*\* A. Alpha-1 adrenergic receptor blockade【48:9†source】 \-\-- \#\#\# \*\*Slide 30: TCA Overdose\*\* 1\. \*\*What is the primary cause of death in TCA overdose?\*\* \- A. Respiratory depression \- B. Cardiovascular toxicity (arrhythmias) \- C. Liver failure \- D. Seizures \*\*Answer:\*\* B. Cardiovascular toxicity (arrhythmias) 2\. \*\*Which electrolyte imbalance is commonly associated with TCA overdose?\*\* \- A. Hyperkalemia \- B. Hyponatremia \- C. Hypocalcemia \- D. Hyperphosphatemia \*\*Answer:\*\* B. Hyponatremia 3\. \*\*What treatment is contraindicated in TCA overdose due to its worsening effect on arrhythmias?\*\* \- A. Sodium bicarbonate \- B. Class I antiarrhythmics (e.g., procainamide) \- C. Activated charcoal \- D. Benzodiazepines \*\*Answer:\*\* B. Class I antiarrhythmics (e.g., procainamide)【48:9†source】 \#\#\# \*\*Slide 31: Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)\*\* 1\. \*\*What is the mechanism of action of SNRIs?\*\* \- A. Inhibition of serotonin and norepinephrine reuptake \- B. Inhibition of dopamine reuptake \- C. Inhibition of monoamine oxidase \- D. Blocking serotonin receptors \*\*Answer:\*\* A. Inhibition of serotonin and norepinephrine reuptake 2\. \*\*Which SNRI is indicated for both depression and neuropathic pain?\*\* \- A. Duloxetine (Cymbalta) \- B. Sertraline (Zoloft) \- C. Paroxetine (Paxil) \- D. Fluoxetine (Prozac) \*\*Answer:\*\* A. Duloxetine (Cymbalta) 3\. \*\*What additional condition, besides depression, is venlafaxine used to treat?\*\* \- A. Obsessive-compulsive disorder (OCD) \- B. Social anxiety disorder \- C. Bipolar disorder \- D. Schizophrenia \*\*Answer:\*\* B. Social anxiety disorder \-\-- \#\#\# \*\*Slide 32: SNRI Pharmacokinetics\*\* 1\. \*\*SNRIs are metabolized through which enzyme system?\*\* \- A. Cytochrome P450 \- B. P-glycoprotein \- C. Monoamine oxidase \- D. Acetylcholinesterase \*\*Answer:\*\* A. Cytochrome P450 2\. \*\*In patients with renal insufficiency, how should SNRI doses be adjusted?\*\* \- A. Dose should be increased \- B. No adjustment is needed \- C. Dose should be reduced \- D. SNRI should be discontinued \*\*Answer:\*\* C. Dose should be reduced 3\. \*\*Which of the following is a common side effect of SNRIs?\*\* \- A. Hypotension \- B. Hypertension \- C. Bradycardia \- D. Constipation \*\*Answer:\*\* B. Hypertension \-\-- \#\#\# \*\*Slide 33: SNRI Side Effects\*\* 1\. \*\*Which of the following is a dose-dependent side effect of SNRIs?\*\* \- A. Hypertension \- B. Hypoglycemia \- C. Sedation \- D. Hypercalcemia \*\*Answer:\*\* A. Hypertension 2\. \*\*Which side effect is commonly associated with both SSRIs and SNRIs?\*\* \- A. Increased sweating \- B. Dry mouth \- C. Tachycardia \- D. Rash \*\*Answer:\*\* A. Increased sweating 3\. \*\*Why should SNRIs not be combined with monoamine oxidase inhibitors (MAOIs)?\*\* \- A. Risk of hypertensive crisis \- B. Risk of serotonin syndrome \- C. Increased risk of arrhythmias \- D. Increased risk of liver toxicity \*\*Answer:\*\* B. Risk of serotonin syndrome \-\-- \#\#\# \*\*Slide 34: Tricyclic Antidepressants (TCAs)\*\* 1\. \*\*What is the mechanism of action of tricyclic antidepressants (TCAs)?\*\* \- A. Inhibition of serotonin and norepinephrine reuptake \- B. Inhibition of dopamine reuptake \- C. Inhibition of serotonin breakdown \- D. Blocking acetylcholine receptors \*\*Answer:\*\* A. Inhibition of serotonin and norepinephrine reuptake 2\. \*\*Which TCA is commonly used to treat obsessive-compulsive disorder (OCD)?\*\* \- A. Clomipramine \- B. Nortriptyline \- C. Desipramine \- D. Amitriptyline \*\*Answer:\*\* A. Clomipramine 3\. \*\*What is a common adverse effect associated with TCAs?\*\* \- A. QT prolongation \- B. Hypotension \- C. Hyperglycemia \- D. Anemia \*\*Answer:\*\* A. QT prolongation \-\-- \#\#\# \*\*Slide 35: TCA Pharmacokinetics\*\* 1\. \*\*Which enzyme system is responsible for the metabolism of tricyclic antidepressants (TCAs)?\*\* \- A. Cytochrome P450 \- B. Acetylcholinesterase \- C. Monoamine oxidase \- D. P-glycoprotein \*\*Answer:\*\* A. Cytochrome P450 2\. \*\*Why are TCAs generally administered at night?\*\* \- A. They have a short half-life \- B. They cause sedation \- C. They are best absorbed with food \- D. To avoid drug interactions \*\*Answer:\*\* B. They cause sedation 3\. \*\*In which population is TCA use particularly risky due to slow metabolism?\*\* \- A. Elderly \- B. Children \- C. Men \- D. Smokers \*\*Answer:\*\* A. Elderly \-\-- \#\#\# \*\*Slide 36: TCA Overdose\*\* 1\. \*\*What is the primary cause of death in TCA overdose?\*\* \- A. Respiratory depression \- B. Cardiotoxicity (arrhythmias) \- C. Seizures \- D. Hyperthermia \*\*Answer:\*\* B. Cardiotoxicity (arrhythmias) 2\. \*\*Which electrolyte abnormality is commonly seen in TCA overdose?\*\* \- A. Hyperkalemia \- B. Hyponatremia \- C. Hypercalcemia \- D. Hypomagnesemia \*\*Answer:\*\* B. Hyponatremia 3\. \*\*What is contraindicated in the treatment of TCA-induced arrhythmias?\*\* \- A. Sodium bicarbonate \- B. Class I antiarrhythmic drugs \- C. Beta-blockers \- D. Benzodiazepines \*\*Answer:\*\* B. Class I antiarrhythmic drugs \-\-- \#\#\# \*\*Slide 37: Monoamine Oxidase Inhibitors (MAOIs)\*\* 1\. \*\*What is the mechanism of action of monoamine oxidase inhibitors (MAOIs)?\*\* \- A. Inhibition of serotonin and norepinephrine reuptake \- B. Inhibition of monoamine oxidase, preventing neurotransmitter breakdown \- C. Stimulation of dopamine release \- D. Blockade of NMDA receptors \*\*Answer:\*\* B. Inhibition of monoamine oxidase, preventing neurotransmitter breakdown 2\. \*\*Which enzyme does MAO-A primarily degrade?\*\* \- A. Dopamine \- B. Acetylcholine \- C. Serotonin and norepinephrine \- D. Glutamate \*\*Answer:\*\* C. Serotonin and norepinephrine 3\. \*\*Which of the following foods should be avoided by patients taking MAOIs due to the risk of hypertensive crisis?\*\* \- A. Cheese \- B. Bananas \- C. Chicken \- D. Broccoli \*\*Answer:\*\* A. Cheese \-\-- \#\#\# \*\*Slide 38: MAOI Drug Interactions\*\* 1\. \*\*What serious condition can result from combining MAOIs with SSRIs?\*\* \- A. Hypertensive crisis \- B. Serotonin syndrome \- C. Hyperkalemia \- D. Hypoglycemia \*\*Answer:\*\* B. Serotonin syndrome 2\. \*\*Which of the following drugs should be avoided with MAOIs due to the risk of hypertensive crisis?\*\* \- A. Pseudoephedrine \- B. Metoprolol \- C. Omeprazole \- D. Lorazepam \*\*Answer:\*\* A. Pseudoephedrine 3\. \*\*MAOIs should not be combined with which type of foods?\*\* \- A. High-protein foods \- B. Tyramine-rich foods \- C. Fatty foods \- D. Carbohydrate-rich foods \*\*Answer:\*\* B. Tyramine-rich foods \-\-- \#\#\# \*\*Slide 39: MAOI Side Effects\*\* 1\. \*\*Which of the following is a common side effect of MAOIs?\*\* \- A. Weight gain \- B. Hypertension \- C. Hypoglycemia \- D. Hypercalcemia \*\*Answer:\*\* A. Weight gain 2\. \*\*What is a life-threatening complication associated with the sudden discontinuation of MAOIs?\*\* \- A. Serotonin syndrome \- B. Discontinuation syndrome with psychosis and confusion \- C. Hypertensive crisis \- D. Hyperglycemia \*\*Answer:\*\* B. Discontinuation syndrome with psychosis and confusion 3\. \*\*Why are MAOIs rarely used as first-line therapy for depression?\*\* \- A. High risk of drug and food interactions \- B. Low efficacy compared to SSRIs \- C. Increased risk of serotonin syndrome \- D. High cost \*\*Answer:\*\* A. High risk of drug and food interactions \-\-- \#\#\# \*\*Slide 40: Bupropion (Wellbutrin)\*\* 1\. \*\*Bupropion primarily inhibits the reuptake of which neurotransmitters?\*\* \- A. Serotonin and norepinephrine \- B. Norepinephrine and dopamine \- C. Dopamine and serotonin \- D. Acetylcholine and serotonin \*\*Answer:\*\* B. Norepinephrine and dopamine 2\. \*\*Bupropion is contraindicated in patients with which condition?\*\* \- A. Hypertension \- B. Seizure disorder \- C. Depression \- D. Schizophrenia \*\*Answer:\*\* B. Seizure disorder 3\. \*\*What is a common reason bupropion is chosen over SSRIs for some patients?\*\* \- A. Lower risk of sexual side effects \- B. Increased sedative effects \- C. Reduced efficacy for anxiety \- D. Increased risk of weight gain \*\*Answer:\*\* A. Lower risk of sexual side effects \#\#\# \*\*Slide 32: SNRI Pharmacokinetics\*\* 1\. \*\*Which enzyme is primarily responsible for metabolizing SNRIs like duloxetine?\*\* \- A. Cytochrome P450 1A2 and 2D6 \- B. Monoamine oxidase A \- C. Acetylcholinesterase \- D. Catechol-O-methyltransferase \*\*Answer:\*\* A. Cytochrome P450 1A2 and 2D6 2\. \*\*How should the dose of SNRIs be adjusted in patients with renal insufficiency?\*\* \- A. Increased by 50% \- B. No adjustment needed \- C. Dose should be reduced \- D. Discontinue the medication \*\*Answer:\*\* C. Dose should be reduced 3\. \*\*What is a common pharmacokinetic feature of SNRIs that may contribute to side effects like hypertension?\*\* \- A. Active metabolites increase serotonin concentration in the brain \- B. Metabolites and the parent drug are eliminated by the kidneys \- C. They are metabolized through the liver and excreted through the bile \- D. SNRIs are stored in fat and slowly released \*\*Answer:\*\* B. Metabolites and the parent drug are eliminated by the kidneys【58:0†source】【58:2†source】 \-\-- \#\#\# \*\*Slide 33: SNRI Side Effects\*\* 1\. \*\*What cardiovascular side effect is commonly associated with SNRIs, especially at high doses?\*\* \- A. Bradycardia \- B. Hypotension \- C. Hypertension \- D. Heart block \*\*Answer:\*\* C. Hypertension 2\. \*\*Which central nervous system (CNS) side effect may occur with SNRIs and is related to their dose?\*\* \- A. Sedation \- B. Anxiety and insomnia \- C. Seizures \- D. Fatigue \*\*Answer:\*\* B. Anxiety and insomnia 3\. \*\*SNRIs can cause a discontinuation syndrome similar to SSRIs. Which of the following symptoms is commonly associated with this syndrome?\*\* \- A. Hyperactivity and agitation \- B. Diarrhea and vomiting \- C. Dizziness and somnolence \- D. Hyperglycemia and increased appetite \*\*Answer:\*\* C. Dizziness and somnolence【58:2†source】【58:2†source】 \#\#\# \*\*Slide 41: Monoamine Oxidase Inhibitors (MAOIs)\*\* 1\. \*\*What is the primary mechanism of action of MAOIs in the treatment of mood disorders?\*\* \- A. Inhibition of serotonin and norepinephrine reuptake \- B. Inhibition of the enzyme monoamine oxidase, preventing the breakdown of neurotransmitters \- C. Activation of dopamine receptors \- D. Inhibition of GABA receptors \*\*Answer:\*\* B. Inhibition of the enzyme monoamine oxidase, preventing the breakdown of neurotransmitters【62:0†source】 2\. \*\*Which type of food must be avoided while taking MAOIs due to the risk of hypertensive crisis?\*\* \- A. High-protein foods \- B. Tyramine-rich foods (e.g., cheese, red wine) \- C. Fatty foods \- D. Carbohydrate-rich foods \*\*Answer:\*\* B. Tyramine-rich foods (e.g., cheese, red wine)【62:0†source】 3\. \*\*Which isoform of monoamine oxidase is responsible for degrading serotonin, norepinephrine, and dopamine?\*\* \- A. MAO-B \- B. MAO-A \- C. COMT \- D. SERT \*\*Answer:\*\* B. MAO-A【62:0†source】 \-\-- \#\#\# \*\*Slide 42: MAOI Side Effects\*\* 1\. \*\*Which side effect is most commonly associated with MAOIs?\*\* \- A. Hypertension \- B. Orthostatic hypotension \- C. Hypercalcemia \- D. Bradycardia \*\*Answer:\*\* B. Orthostatic hypotension【62:0†source】 2\. \*\*MAOIs are associated with the highest rate of which of the following side effects?\*\* \- A. Sexual dysfunction \- B. Weight loss \- C. Constipation \- D. Hepatotoxicity \*\*Answer:\*\* A. Sexual dysfunction【62:0†source】 3\. \*\*Which of the following conditions is associated with discontinuation syndrome upon sudden cessation of MAOIs?\*\* \- A. Psychosis, excitement, and confusion \- B. Seizures and coma \- C. Hyperglycemia and tremors \- D. Bradycardia and hypotension \*\*Answer:\*\* A. Psychosis, excitement, and confusion【62:0†source】 \-\-- \#\#\# \*\*Slide 43: Bupropion (Wellbutrin)\*\* 1\. \*\*What is the primary mechanism of action of bupropion (Wellbutrin)?\*\* \- A. Selective serotonin reuptake inhibitor (SSRI) \- B. Norepinephrine and dopamine reuptake inhibitor \- C. Monoamine oxidase inhibitor (MAOI) \- D. GABA agonist \*\*Answer:\*\* B. Norepinephrine and dopamine reuptake inhibitor【62:0†source】 2\. \*\*In which patient population should bupropion be avoided due to the risk of seizures?\*\* \- A. Patients with a history of hypertension \- B. Patients with a history of seizure disorder \- C. Patients with schizophrenia \- D. Patients with bipolar disorder \*\*Answer:\*\* B. Patients with a history of seizure disorder【62:0†source】 3\. \*\*Which of the following is an advantage of bupropion compared to SSRIs?\*\* \- A. Lower risk of sexual side effects \- B. Greater sedative effects \- C. Faster onset of action \- D. Increased serotonin reuptake \*\*Answer:\*\* A. Lower risk of sexual side effects【62:0†source】 \-\-- \#\#\# \*\*Slide 44: Dextromethorphan/Bupropion ER (Auvelity)\*\* 1\. \*\*Dextromethorphan in Auvelity works as an antagonist of which receptor?\*\* \- A. GABA-A receptor \- B. NMDA receptor \- C. Dopamine receptor \- D. Alpha-1 receptor \*\*Answer:\*\* B. NMDA receptor【62:0†source】 2\. \*\*Which drug is combined with dextromethorphan in Auvelity to enhance its antidepressant effects?\*\* \- A. Fluoxetine \- B. Bupropion \- C. Venlafaxine \- D. Mirtazapine \*\*Answer:\*\* B. Bupropion【62:0†source】 3\. \*\*What serious adverse reaction can occur when combining dextromethorphan with other serotonergic medications?\*\* \- A. Hypertensive crisis \- B. Serotonin syndrome \- C. Hypercalcemia \- D. Bradycardia \*\*Answer:\*\* B. Serotonin syndrome【62:0†source】 \-\-- \#\#\# \*\*Slide 45: Trazodone (Desyrel)\*\* 1\. \*\*What is the primary use of trazodone at low doses (25-150 mg)?\*\* \- A. Antidepressant \- B. Insomnia treatment \- C. Antipsychotic \- D. Weight loss \*\*Answer:\*\* B. Insomnia treatment【62:0†source】 2\. \*\*Which receptor blockade is responsible for trazodone's sedative effects?\*\* \- A. NMDA receptor \- B. Histamine H1 receptor \- C. GABA receptor \- D. Dopamine D2 receptor \*\*Answer:\*\* B. Histamine H1 receptor【62:0†source】 3\. \*\*What is a rare but serious side effect of trazodone?\*\* \- A. Serotonin syndrome \- B. Priapism \- C. Agranulocytosis \- D. Hepatitis \*\*Answer:\*\* B. Priapism【62:0†source】 \-\-- \#\#\# \*\*Slide 46: Nefazodone\*\* 1\. \*\*What receptor does nefazodone block that contributes to its antidepressant effects?\*\* \- A. 5-HT2A receptor \- B. Dopamine D2 receptor \- C. NMDA receptor \- D. Beta-1 receptor \*\*Answer:\*\* A. 5-HT2A receptor【62:0†source】 2\. \*\*Nefazodone is chemically related to which of the following antidepressants?\*\* \- A. Trazodone \- B. Mirtazapine \- C. Bupropion \- D. Venlafaxine \*\*Answer:\*\* A. Trazodone【62:0†source】 3\. \*\*Why is nefazodone no longer commonly prescribed?\*\* \- A. Risk of hepatotoxicity \- B. Risk of seizures \- C. High rate of weight gain \- D. Increased risk of serotonin syndrome \*\*Answer:\*\* A. Risk of hepatotoxicity【62:0†source】 \-\-- \#\#\# \*\*Slide 47: Mirtazapine (Remeron)\*\* 1\. \*\*What is the mechanism of action of mirtazapine?\*\* \- A. Alpha-2 receptor antagonist \- B. Dopamine D2 receptor antagonist \- C. GABA receptor agonist \- D. NMDA receptor antagonist \*\*Answer:\*\* A. Alpha-2 receptor antagonist【62:0†source】 2\. \*\*Which of the following is a common side effect of mirtazapine?\*\* \- A. Weight gain \- B. Hypertension \- C. Tachycardia \- D. Nausea \*\*Answer:\*\* A. Weight gain【62:0†source】 3\. \*\*Mirtazapine is less likely to cause which of the following side effects compared to SSRIs?\*\* \- A. Sexual dysfunction \- B. Weight gain \- C. Sedation \- D. Dry mouth \*\*Answer:\*\* A. Sexual dysfunction【62:0†source】 \-\-- \#\#\# \*\*Slide 48: Vortioxetine (Trintellix)\*\* 1\. \*\*Which of the following receptors does vortioxetine partially agonize?\*\* \- A. 5-HT1A \- B. NMDA \- C. Alpha-2 adrenergic \- D. Dopamine D2 \*\*Answer:\*\* A. 5-HT1A【62:0†source】 2\. \*\*Which of the following is a common side effect of vortioxetine?\*\* \- A. Diarrhea \- B. Headache \- C. Tachycardia \- D. Weight loss \*\*Answer:\*\* B. Headache【62:0†source】 3\. \*\*Vortioxetine primarily inhibits which transporter in the treatment of depression?\*\* \- A. SERT (Serotonin transporter) \- B. DAT (Dopamine transporter) \- C. NET (Norepinephrine transporter) \- D. GAT (GABA transporter) \*\*Answer:\*\* A. SERT (Serotonin transporter)【62:0†source】 \#\#\# \*\*Slide 49: Bupropion Pharmacokinetics\*\* 1\. \*\*What is the primary enzyme responsible for the metabolism of bupropion?\*\* \- A. CYP3A4 \- B. CYP2D6 \- C. MAO-B \- D. CYP1A2 \*\*Answer:\*\* B. CYP2D6【67:0†source】 2\. \*\*Bupropion is contraindicated in patients with a history of which condition?\*\* \- A. Hypertension \- B. Anxiety \- C. Seizure disorder \- D. Obesity \*\*Answer:\*\* C. Seizure disorder【67:0†source】 3\. \*\*In addition to its use in depression, bupropion is approved for which of the following conditions?\*\* \- A. Alcohol dependence \- B. Smoking cessation \- C. Migraine prevention \- D. ADHD \*\*Answer:\*\* B. Smoking cessation【67:0†source】 \-\-- \#\#\# \*\*Slide 50: New Medication: Dextromethorphan/Bupropion ER (Auvelity)\*\* 1\. \*\*What is the mechanism of action of dextromethorphan in Auvelity?\*\* \- A. NMDA receptor antagonist \- B. Serotonin reuptake inhibitor \- C. GABA receptor agonist \- D. Alpha-2 adrenergic antagonist \*\*Answer:\*\* A. NMDA receptor antagonist【67:0†source】 2\. \*\*What is a potential adverse reaction when combining dextromethorphan with other serotonergic medications?\*\* \- A. Serotonin syndrome \- B. Hypertensive crisis \- C. Bradycardia \- D. Respiratory depression \*\*Answer:\*\* A. Serotonin syndrome【67:0†source】 3\. \*\*How soon can symptom improvement begin after starting Auvelity for depression?\*\* \- A. 2 weeks \- B. 4 weeks \- C. 1 week \- D. 6 weeks \*\*Answer:\*\* C. 1 week【67:0†source】 \-\-- \#\#\# \*\*Slide 51: Trazodone (Desyrel)\*\* 1\. \*\*What receptor does trazodone antagonize that contributes to its sedative effects?\*\* \- A. Histamine H1 receptor \- B. Alpha-2 adrenergic receptor \- C. Serotonin 5-HT2A receptor \- D. GABA-A receptor \*\*Answer:\*\* A. Histamine H1 receptor【67:0†source】 2\. \*\*At low doses, trazodone is commonly used to treat which condition?\*\* \- A. Depression \- B. Anxiety \- C. Insomnia \- D. Bipolar disorder \*\*Answer:\*\* C. Insomnia【67:0†source】 3\. \*\*What is a rare but serious side effect associated with trazodone?\*\* \- A. Serotonin syndrome \- B. Priapism \- C. Hepatotoxicity \- D. Weight gain \*\*Answer:\*\* B. Priapism【67:0†source】 \-\-- \#\#\# \*\*Slide 52: Nefazodone\*\* 1\. \*\*Nefazodone is chemically related to which other antidepressant?\*\* \- A. Mirtazapine \- B. Trazodone \- C. Bupropion \- D. Sertraline \*\*Answer:\*\* B. Trazodone【67:0†source】 2\. \*\*What is a serious risk associated with nefazodone that has limited its use?\*\* \- A. Hepatotoxicity \- B. Seizures \- C. Hypertension \- D. Sexual dysfunction \*\*Answer:\*\* A. Hepatotoxicity【67:0†source】 3\. \*\*Nefazodone inhibits which enzyme, leading to significant drug interactions?\*\* \- A. CYP2D6 \- B. CYP3A4 \- C. MAO-B \- D. CYP1A2 \*\*Answer:\*\* B. CYP3A4【67:0†source】 \-\-- \#\#\# \*\*Slide 53: Mirtazapine (Remeron)\*\* 1\. \*\*What is the mechanism of action of mirtazapine?\*\* \- A. Serotonin reuptake inhibitor \- B. Alpha-2 adrenergic receptor antagonist \- C. Dopamine reuptake inhibitor \- D. GABA receptor agonist \*\*Answer:\*\* B. Alpha-2 adrenergic receptor antagonist【67:0†source】 2\. \*\*Which of the following is a common side effect of mirtazapine?\*\* \- A. Weight loss \- B. Hypertension \- C. Weight gain \- D. Sexual dysfunction \*\*Answer:\*\* C. Weight gain【67:0†source】 3\. \*\*Mirtazapine is less likely to cause which side effect compared to SSRIs?\*\* \- A. Sedation \- B. Sexual dysfunction \- C. Weight gain \- D. Dry mouth \*\*Answer:\*\* B. Sexual dysfunction【67:0†source】 \-\-- \#\#\# \*\*Slide 54: Vortioxetine (Trintellix)\*\* 1\. \*\*What is the primary mechanism of action of vortioxetine?\*\* \- A. Dopamine reuptake inhibitor \- B. Serotonin transporter (SERT) inhibitor \- C. NMDA receptor antagonist \- D. Alpha-2 adrenergic agonist \*\*Answer:\*\* B. Serotonin transporter (SERT) inhibitor【67:0†source】 2\. \*\*Which of the following receptors does vortioxetine partially agonize?\*\* \- A. 5-HT1A \- B. NMDA \- C. GABA-A \- D. Alpha-1 adrenergic \*\*Answer:\*\* A. 5-HT1A【67:0†source】 3\. \*\*Which of the following is a common side effect of vortioxetine?\*\* \- A. Diarrhea \- B. Nausea \- C. Bradycardia \- D. Weight gain \*\*Answer:\*\* B. Nausea【67:0†source】 \-\-- \#\#\# \*\*Slide 55: Vilazodone (Viibryd)\*\* 1\. \*\*Vilazodone acts as a partial agonist at which receptor?\*\* \- A. 5-HT1A receptor \- B. NMDA receptor \- C. Alpha-2 adrenergic receptor \- D. GABA-B receptor \*\*Answer:\*\* A. 5-HT1A receptor【67:0†source】 2\. \*\*What is a significant adverse effect associated with vilazodone that requires monitoring?\*\* \- A. Long QT syndrome \- B. Hypertensive crisis \- C. Weight gain \- D. Hepatotoxicity \*\*Answer:\*\* A. Long QT syndrome【67:0†source】 3\. \*\*Vilazodone's mechanism enhances serotonergic activity by inhibiting which transporter?\*\* \- A. SERT (Serotonin transporter) \- B. DAT (Dopamine transporter) \- C. NET (Norepinephrine transporter) \- D. GAT (GABA transporter) \*\*Answer:\*\* A. SERT (Serotonin transporter)【67:0†source】 \#\#\# \*\*Slide 55: NMDA Receptor Antagonists\*\* 1\. \*\*What is the primary mechanism of action of NMDA receptor antagonists like ketamine in depression treatment?\*\* \- A. Serotonin reuptake inhibition \- B. NMDA receptor antagonism \- C. Dopamine receptor blockade \- D. GABA receptor activation \*\*Answer:\*\* B. NMDA receptor antagonism 2\. \*\*Esketamine (Spravato) is indicated for which of the following conditions?\*\* \- A. Generalized anxiety disorder \- B. Treatment-resistant depression and acute suicidal ideation \- C. Obsessive-compulsive disorder \- D. Bipolar disorder \*\*Answer:\*\* B. Treatment-resistant depression and acute suicidal ideation 3\. \*\*What is a major concern regarding the use of ketamine in depression treatment?\*\* \- A. Weight gain \- B. Risk of dissociative symptoms and abuse potential \- C. Increased risk of seizures \- D. Hyperglycemia \*\*Answer:\*\* B. Risk of dissociative symptoms and abuse potential \-\-- \#\#\# \*\*Slide 56: How to Choose an Antidepressant\*\* 1\. \*\*Which of the following antidepressants is least likely to cause sexual side effects?\*\* \- A. Bupropion \- B. Fluoxetine \- C. Paroxetine \- D. Citalopram \*\*Answer:\*\* A. Bupropion 2\. \*\*What is a key consideration when choosing an antidepressant for a patient?\*\* \- A. Only the cost of the drug \- B. Indication, cost, availability, adverse effects, drug interactions, and history of response \- C. The patient\'s weight \- D. The patient\'s age \*\*Answer:\*\* B. Indication, cost, availability, adverse effects, drug interactions, and history of response 3\. \*\*Which antidepressant class is most commonly prescribed for major depressive disorder (MDD) and anxiety disorders?\*\* \- A. Tricyclic antidepressants (TCAs) \- B. Monoamine oxidase inhibitors (MAOIs) \- C. Selective serotonin reuptake inhibitors (SSRIs) \- D. NMDA receptor antagonists \*\*Answer:\*\* C. Selective serotonin reuptake inhibitors (SSRIs) \-\-- \#\#\# \*\*Slide 57: Clinical Indications for Antidepressants\*\* 1\. \*\*What is the goal of acute treatment with antidepressants in patients with depression?\*\* \- A. Reduce the number of depressive symptoms by half \- B. Achieve full remission of depressive symptoms \- C. Manage symptoms to a tolerable level \- D. Maintain the patient on therapy for life \*\*Answer:\*\* B. Achieve full remission of depressive symptoms 2\. \*\*How long should a trial of antidepressant therapy last before determining efficacy?\*\* \- A. 1-2 weeks \- B. 8-12 weeks \- C. 6 months \- D. 4 weeks \*\*Answer:\*\* B. 8-12 weeks 3\. \*\*In patients who have experienced two or more serious episodes of major depressive disorder (MDD) in the last 5 years, what is recommended?\*\* \- A. Short-term therapy for 3 months \- B. Long-term antidepressant therapy \- C. Discontinue medication and focus on psychotherapy \- D. Use only psychotherapy \*\*Answer:\*\* B. Long-term antidepressant therapy \-\-- \#\#\# \*\*Slide 58: Antidepressant Side Effects and Discontinuation\*\* 1\. \*\*Which antidepressant class is associated with the highest risk of fatal overdose?\*\* \- A. Selective serotonin reuptake inhibitors (SSRIs) \- B. Serotonin-norepinephrine reuptake inhibitors (SNRIs) \- C. Tricyclic antidepressants (TCAs) \- D. NMDA receptor antagonists \*\*Answer:\*\* C. Tricyclic antidepressants (TCAs) 2\. \*\*What is a common symptom of antidepressant discontinuation syndrome?\*\* \- A. Euphoria \- B. Dizziness and paresthesias \- C. Seizures \- D. Constipation \*\*Answer:\*\* B. Dizziness and paresthesias 3\. \*\*Which antidepressants are most likely to cause severe withdrawal symptoms if stopped abruptly?\*\* \- A. Long half-life SSRIs (e.g., fluoxetine) \- B. Short half-life SSRIs (e.g., paroxetine, sertraline) \- C. NMDA receptor antagonists \- D. MAOIs \*\*Answer:\*\* B. Short half-life SSRIs (e.g., paroxetine, sertraline) \-\-- \#\#\# \*\*Slide 59: Antidepressant Drug Interactions\*\* 1\. \*\*What effect do paroxetine and fluoxetine have on the cytochrome P450 (CYP) enzyme system?\*\* \- A. They are potent CYP2D6 inhibitors \- B. They induce CYP2D6 activity \- C. They inhibit CYP3A4 \- D. They have no effect on the CYP enzyme system \*\*Answer:\*\* A. They are potent CYP2D6 inhibitors 2\. \*\*Which antidepressants are relatively free from significant drug interactions?\*\* \- A. Paroxetine and fluoxetine \- B. Citalopram and sertraline \- C. Venlafaxine and duloxetine \- D. Bupropion and mirtazapine \*\*Answer:\*\* B. Citalopram and sertraline 3\. \*\*Which of the following drugs is contraindicated with SSRIs due to the risk of serotonin syndrome?\*\* \- A. Beta-blockers \- B. MAOIs \- C. Antihistamines \- D. NSAIDs \*\*Answer:\*\* B. MAOIs \-\-- \#\#\# \*\*Slide 60: Serotonin Syndrome\*\* 1\. \*\*What is a key sign of serotonin syndrome?\*\* \- A. Hypotension \- B. Hyperthermia and autonomic instability \- C. Bradycardia \- D. Hypoglycemia \*\*Answer:\*\* B. Hyperthermia and autonomic instability 2\. \*\*Which of the following is commonly used to treat serotonin syndrome by blocking serotonin receptors?\*\* \- A. Cyproheptadine \- B. Diazepam \- C. Lorazepam \- D. Fluoxetine \*\*Answer:\*\* A. Cyproheptadine 3\. \*\*Which class of drugs is most commonly associated with serotonin syndrome?\*\* \- A. Antipsychotics \- B. Antidepressants (e.g., SSRIs, SNRIs) \- C. Beta-blockers \- D. Benzodiazepines \*\*Answer:\*\* B. Antidepressants (e.g., SSRIs, SNRIs) \#\#\# \*\*Slide 61: Antidepressant Selection and Considerations\*\* 1\. \*\*What is the primary consideration when selecting an antidepressant for a patient?\*\* \- A. Cost and availability only \- B. Indication, cost, availability, adverse effects, drug interactions, and history of response \- C. Weight of the patient \- D. Age of the patient \*\*Answer:\*\* B. Indication, cost, availability, adverse effects, drug interactions, and history of response【75:0†source】 2\. \*\*Which antidepressants are known to have the lowest sexual side effects?\*\* \- A. SSRIs \- B. Bupropion, mirtazapine, and nefazodone \- C. SNRIs \- D. Tricyclic antidepressants (TCAs) \*\*Answer:\*\* B. Bupropion, mirtazapine, and nefazodone【75:0†source】 3\. \*\*Which antidepressants are most commonly prescribed for major depressive disorder (MDD) and anxiety disorders?\*\* \- A. Monoamine oxidase inhibitors (MAOIs) \- B. Selective serotonin reuptake inhibitors (SSRIs) \- C. Tricyclic antidepressants (TCAs) \- D. Bupropion and nefazodone \*\*Answer:\*\* B. Selective serotonin reuptake inhibitors (SSRIs)【75:0†source】 \-\-- \#\#\# \*\*Slide 62: Clinical Indications for Antidepressants\*\* 1\. \*\*What is the goal of acute treatment with antidepressants in patients with depression?\*\* \- A. Reduce symptoms by 50% \- B. Achieve full remission of depressive symptoms \- C. Manage symptoms to a tolerable level \- D. Maintain the patient on therapy for life \*\*Answer:\*\* B. Achieve full remission of depressive symptoms【75:0†source】 2\. \*\*How long does it typically take to see maximum benefit from antidepressants?\*\* \- A. 1 week \- B. 2-3 weeks \- C. 1-2 months \- D. 4 months \*\*Answer:\*\* C. 1-2 months【75:0†source】 3\. \*\*For patients with two or more serious episodes of major depressive disorder (MDD) in the last 5 years, what is recommended?\*\* \- A. Short-term therapy for 3 months \- B. Long-term antidepressant therapy \- C. Discontinue medication after symptoms improve \- D. Use only psychotherapy \*\*Answer:\*\* B. Long-term antidepressant therapy【75:0†source】 \-\-- \#\#\# \*\*Slide 63: Antidepressant Drug Interactions\*\* 1\. \*\*Which antidepressants are potent inhibitors of CYP2D6, leading to significant drug interactions?\*\* \- A. Citalopram and sertraline \- B. Paroxetine and fluoxetine \- C. Venlafaxine and duloxetine \- D. Bupropion and mirtazapine \*\*Answer:\*\* B. Paroxetine and fluoxetine【75:0†source】 2\. \*\*Which antidepressants are relatively free from significant drug interactions?\*\* \- A. Paroxetine and fluoxetine \- B. Citalopram and sertraline \- C. Venlafaxine and duloxetine \- D. Bupropion and mirtazapine \*\*Answer:\*\* B. Citalopram and sertraline【75:0†source】 3\. \*\*What is a serious contraindication when using SSRIs due to the risk of serotonin syndrome?\*\* \- A. Use with beta-blockers \- B. Use with MAOIs \- C. Use with benzodiazepines \- D. Use with NSAIDs \*\*Answer:\*\* B. Use with MAOIs【75:0†source】 \-\-- \#\#\# \*\*Slide 64: Serotonin Syndrome\*\* 1\. \*\*What are the hallmark signs of serotonin syndrome?\*\* \- A. Hypotension and bradycardia \- B. Hyperthermia, autonomic instability, and neuromuscular abnormalities \- C. Hypoglycemia and confusion \- D. Hyperactivity and tremors \*\*Answer:\*\* B. Hyperthermia, autonomic instability, and neuromuscular abnormalities【75:0†source】 2\. \*\*Which medication is commonly used to treat serotonin syndrome by blocking serotonin receptors?\*\* \- A. Cyproheptadine \- B. Diazepam \- C. Fluoxetine \- D. Lorazepam \*\*Answer:\*\* A. Cyproheptadine【75:0†source】 3\. \*\*Which drug class is most commonly associated with causing serotonin syndrome?\*\* \- A. Antipsychotics \- B. Antidepressants (SSRIs, SNRIs) \- C. Beta-blockers \- D. Benzodiazepines \*\*Answer:\*\* B. Antidepressants (SSRIs, SNRIs)【75:0†source】

Use Quizgecko on...
Browser
Browser